Eugene R Schiff

Author PubWeight™ 99.69‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009 14.31
2 Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002 8.21
3 Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010 6.52
4 Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003 4.33
5 Histological outcome during long-term lamivudine therapy. Gastroenterology 2003 3.88
6 Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011 3.36
7 A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008 2.97
8 Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004 2.28
9 A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006 1.92
10 Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2010 1.79
11 A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005 1.76
12 Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl 2009 1.67
13 Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002 1.60
14 Spontaneous clearance of hepatitis C virus after liver transplantation in two patients coinfected with hepatitis C virus and human immunodeficiency virus. Liver Transpl 2008 1.59
15 A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004 1.47
16 Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 2007 1.38
17 Acetaminophen safety and hepatotoxicity--where do we go from here? Expert Opin Drug Saf 2007 1.36
18 Alcohol and hepatitis C. Semin Liver Dis 2004 1.34
19 Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004 1.30
20 Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006 1.21
21 The influence of menopause on the development of hepatic fibrosis in nonobese women with nonalcoholic fatty liver disease. Hepatology 2014 1.17
22 Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology 2005 1.15
23 The current economic burden of cirrhosis. Gastroenterol Hepatol (N Y) 2011 1.11
24 Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc 2010 1.06
25 Does the heterozygous state of alpha-1 antitrypsin deficiency have a role in chronic liver diseases? Interim results of a large case-control study. J Pediatr Gastroenterol Nutr 2006 1.01
26 Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice. Am J Gastroenterol 2003 1.00
27 Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003 0.97
28 A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl 2003 0.96
29 Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004 0.94
30 Histopathological changes after microwave coagulation therapy for patients with hepatocellular carcinoma: review of 15 explanted livers. Am J Gastroenterol 2003 0.91
31 Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl 2004 0.91
32 A retrospective review of sirolimus (Rapamune) therapy in orthotopic liver transplant recipients diagnosed with chronic rejection. Liver Transpl 2003 0.90
33 Multiple normal deliveries in a woman with severe portal hypertension due to congenital hepatic fibrosis: the importance of preserved hepatocellular function. Am J Gastroenterol 2005 0.90
34 FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus. World J Gastroenterol 2011 0.90
35 Outcomes after orthotopic liver transplantation in 15 HIV-infected patients. Transplantation 2007 0.89
36 Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial. Antivir Ther 2013 0.88
37 Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004 0.88
38 Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. Clin Transplant 2007 0.86
39 Advances in hepatology: current developments in the treatment of hepatitis and hepatobiliary disease. Gastroenterol Hepatol (N Y) 2009 0.86
40 Avoid the tragedy of hepatitis B reactivation in immunosuppressed patients. Nat Clin Pract Gastroenterol Hepatol 2007 0.84
41 Histologic evidence of active liver injury in chronic hepatitis B patients with normal range or minimally elevated alanine aminotransferase levels. J Clin Gastroenterol 2010 0.83
42 Predictors of cirrhosis in Hispanic patients with nonalcoholic steatohepatitis. Dig Dis Sci 2006 0.83
43 An update on the hepatitis E virus. Curr Gastroenterol Rep 2013 0.83
44 Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. Ann Clin Microbiol Antimicrob 2006 0.81
45 Correlation of Laparoscopic Liver Biopsy to Elasticity Measurements (FibroScan) in Patients With Chronic Liver Disease. Gastroenterol Hepatol (N Y) 2008 0.81
46 Diagnostic laparoscopy in radiation-induced liver disease. Gastrointest Endosc 2002 0.81
47 Screening for hepatitis B virus and hepatitis C virus at a community fair: a single-center experience. Gastroenterol Hepatol (N Y) 2013 0.80
48 Tenofovir therapy for lamivudine resistance following liver transplantation. Ann Pharmacother 2004 0.80
49 Combined central retinal vein and central retinal artery occlusions and neovascular glaucoma associated with interferon treatment. Eur J Ophthalmol 2012 0.80
50 Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study. J Hepatol 2012 0.79
51 Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation. Pharmacotherapy 2008 0.79
52 Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing. Liver Transpl 2004 0.79
53 Acquired hepatocerebral degeneration in a patient with HCV cirrhosis: complete resolution with subsequent recurrence after liver transplantation. Liver Transpl 2006 0.79
54 Prospective Evaluation of FIBROSpect II for Fibrosis Detection in Hepatitis C and B Patients Undergoing Laparoscopic Biopsy. Gastroenterol Hepatol (N Y) 2007 0.78
55 Competing risks analysis of predictors of delisting owing to tumor progression in liver transplant candidates with hepatocellular carcinoma. Am J Transplant 2004 0.78
56 Relapsing polychondritis, chronic hepatitis C virus infection, and mixed cryoglobulemia. Semin Arthritis Rheum 2004 0.78
57 Chronic hepatitis B: a critical appraisal of current approaches to therapy. Clin Gastroenterol Hepatol 2006 0.78
58 Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial. J Cancer Res Clin Oncol 2003 0.78
59 Clinical usage of serum ferritin to assess liver fibrosis in patients with non-alcoholic fatty liver disease: Proceed with caution. Hepatol Res 2014 0.78
60 Imatinib mesylate (gleevec) hepatotoxicity. Dig Dis Sci 2007 0.77
61 Beneficial effects of topical testosterone replacement in patients with end-stage liver disease. Dig Dis Sci 2004 0.77
62 Focal nodular hyperplasia in identical twins. Am J Gastroenterol 2005 0.77
63 High frequency of genotype D and spontaneous hepatitis B virus genomic mutations among Haitians in a multiethnic North American population. J Clin Gastroenterol 2013 0.75
64 Decreasing Liver Stiffness Following Pericardiectomy for Constrictive Pericarditis. Intern Med 2015 0.75
65 Budd-Chiari-like presentation of hepatic adenoma. J Gastroenterol Hepatol 2005 0.75
66 Epithelioid hemangioendothelioma of the liver. Clin Gastroenterol Hepatol 2005 0.75
67 Pretreatment laparoscopic appearance of the liver can predict response to combination therapy with interferon alpha 2B and ribavirin in chronic hepatitis C. Gastrointest Endosc 2003 0.75
68 Professor Dame Sheila Sherlock (1918-2001). Curr Opin Gastroenterol 2002 0.75